Literature DB >> 6414693

Ifosfamide--current aspects and perspectives.

P Hilgard, K Herdrich, W Brade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6414693     DOI： 10.1016/s0305-7372(83)80027-9

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  12 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Ifosfamide by bolus as treatment for advanced non-small cell lung cancer.

Authors:  N Thatcher; H Anderson; D B Smith; W P Steward; K Webb; A Hilton; A Rahman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.

Authors:  J Ninane; R Baurain; J de Kraker; A Ferster; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Phase II studies of ifosfamide alone and in combination in cancer of the cervix.

Authors:  G Blackledge; E J Buxton; J J Mould; J Monaghan; M Paterson; J Tobias; C Alcock; D Spooner; C A Meanwell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  A phase II study of ifosfamide in children with recurrent solid tumours.

Authors:  C R Pinkerton; H Rogers; C James; A Bowman; P R Barbor; O B Eden; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  A phase II study of ifosfamide in endometrial cancer.

Authors:  C Barton; E J Buxton; G Blackledge; J J Mould; C A Meanwell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.

Authors:  R E Coleman; P G Harper; C Gallagher; R Osborne; E M Rankin; A C Silverstone; M L Slevin; R L Souhami; J S Tobias; C W Trask
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  A phase II study of ifosfamide in paediatric solid tumours.

Authors:  C R Pinkerton; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Severe renal failure following high-dose ifosfamide and mesna.

Authors:  P H Willemse; P E de Jong; J D Elema; N H Mulder
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.